Immunome Inc. cash flow statement
In fiscal 2025, Immunome Inc.'s operations generated −$191m of cash; it spent $9.7m on capital projects, leaving free cash flow of −$201m.
Cash flow statement
| Fiscal year | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|
| Cash from operations | −8 | −111 | −191 | −209 |
| Depreciation and amortisation | 0 | 2 | 2 | 3 |
| Stock-based pay | 6 | 16 | 26 | 31 |
| Capital spending | 1 | 7 | 10 | 10 |
| Free cash flow | −8 | −118 | −201 | −219 |
| Free cash flow after stock pay | −15 | −134 | −226 | −250 |
| Shares issued | 0 | 20 | 46 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −34 | −42 | −53 | −49 | −41 | −48 | −59 | −62 |
| Depreciation and amortisation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 5 | 5 | 6 | 5 | 7 | 8 | 8 | 9 |
| Capital spending | 2 | 1 | 4 | 1 | 1 | 4 | 3 | 2 |
| Free cash flow | −36 | −43 | −57 | −50 | −42 | −52 | −62 | −64 |
| Free cash flow after stock pay | −41 | −49 | −62 | −56 | −48 | −60 | −70 | −73 |
| Shares issued | — | 20 | — | — | — | 0 | — | — |
More: Biotechnology stocks compared, Health Care sector, rankings of US companies